KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Raw Materials: 2015-2018

  • Travere Therapeutics' Raw Materials rose 17.85% to $3.7 million in Q1 2018 from the same period last year, while for Mar 2018 it was $3.7 million, marking a year-over-year increase of 17.85%. This contributed to the annual value of $3.4 million for FY2017, which is 157.11% up from last year.
  • As of Q1 2018, Travere Therapeutics' Raw Materials stood at $3.7 million, which was up 8.97% from $3.4 million recorded in Q4 2017.
  • In the past 5 years, Travere Therapeutics' Raw Materials registered a high of $3.7 million during Q1 2018, and its lowest value of $232,000 during Q2 2016.
  • In the last 3 years, Travere Therapeutics' Raw Materials had a median value of $3.2 million in 2017 and averaged $2.4 million.
  • Data for Travere Therapeutics' Raw Materials shows a peak YoY soared of 362.28% (in 2016) over the last 5 years.
  • Quarterly analysis of 4 years shows Travere Therapeutics' Raw Materials stood at $289,000 in 2015, then soared by 362.28% to $1.3 million in 2016, then skyrocketed by 157.11% to $3.4 million in 2017, then increased by 17.85% to $3.7 million in 2018.
  • Its last three reported values are $3.7 million in Q1 2018, $3.4 million for Q4 2017, and $3.2 million during Q1 2017.